Case report: Identification of recombinant HCV genotype 1b–2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir

Luis Antonio Uribe-Noguez, Alicia Ocaña-Mondragón, José Antonio Mata-Marín, Allison Cázares-Cortázar, Rosa María Ribas-Aparicio, María Elena Gómez-Torres, Jesus Gaytán-Martínez, María de la Luz Martínez-Rodríguez

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

© 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Hepatitis C virus (HCV) infection is a global health problem. HCV has been classified into seven genotypes and >67 subtypes. Genotyping is necessary to enable selection of appropriate treatments. The commercial molecular techniques currently used do not identify some HCV subtypes, mixed infections and recombinant forms. In this study, the core–E1 and NS5B regions were sequenced and phylogenetically analysed to identify infections by HCV recombinant genotype 1b–2b in two patients who had initially been diagnosed with HCV genotype 2 infection by reverse hybridization with a Versant HCV Genotype 2.0 Assay. Response to treatment was monitored by viral kinetics. Therapeutic failure occurred with initial treatment with PEGylated interferon-α2b and ribavirin, but the use of sofosbuvir and daclatasvir on a re-treatment regimen after reclassification of the infecting virus resulted in a sustained virologic response. The use of a sequencing approach in treatment-naïve infected patients could enable physicians to select the optimal therapy and avoid possible relapses and adverse reactions associated with antiviral therapy.
Original languageAmerican English
Pages (from-to)928-931
Number of pages834
JournalJournal of Infection and Chemotherapy
DOIs
StatePublished - 1 Nov 2018

Fingerprint

Treatment Failure
Hepacivirus
Genotype
Therapeutics
Hepatitis A
Sofosbuvir
BMS-790052
Ribavirin
Virus Diseases
Infection
Coinfection
Interferons
Antiviral Agents
Communicable Diseases
Viruses
Physicians
Recurrence
Drug Therapy

Cite this

Uribe-Noguez, Luis Antonio ; Ocaña-Mondragón, Alicia ; Mata-Marín, José Antonio ; Cázares-Cortázar, Allison ; Ribas-Aparicio, Rosa María ; Gómez-Torres, María Elena ; Gaytán-Martínez, Jesus ; Martínez-Rodríguez, María de la Luz. / Case report: Identification of recombinant HCV genotype 1b–2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir. In: Journal of Infection and Chemotherapy. 2018 ; pp. 928-931.
@article{e1051864e43c4a4891b685afa14aeea1,
title = "Case report: Identification of recombinant HCV genotype 1b–2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir",
abstract = "{\circledC} 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Hepatitis C virus (HCV) infection is a global health problem. HCV has been classified into seven genotypes and >67 subtypes. Genotyping is necessary to enable selection of appropriate treatments. The commercial molecular techniques currently used do not identify some HCV subtypes, mixed infections and recombinant forms. In this study, the core–E1 and NS5B regions were sequenced and phylogenetically analysed to identify infections by HCV recombinant genotype 1b–2b in two patients who had initially been diagnosed with HCV genotype 2 infection by reverse hybridization with a Versant HCV Genotype 2.0 Assay. Response to treatment was monitored by viral kinetics. Therapeutic failure occurred with initial treatment with PEGylated interferon-α2b and ribavirin, but the use of sofosbuvir and daclatasvir on a re-treatment regimen after reclassification of the infecting virus resulted in a sustained virologic response. The use of a sequencing approach in treatment-na{\"i}ve infected patients could enable physicians to select the optimal therapy and avoid possible relapses and adverse reactions associated with antiviral therapy.",
author = "Uribe-Noguez, {Luis Antonio} and Alicia Oca{\~n}a-Mondrag{\'o}n and Mata-Mar{\'i}n, {Jos{\'e} Antonio} and Allison C{\'a}zares-Cort{\'a}zar and Ribas-Aparicio, {Rosa Mar{\'i}a} and G{\'o}mez-Torres, {Mar{\'i}a Elena} and Jesus Gayt{\'a}n-Mart{\'i}nez and Mart{\'i}nez-Rodr{\'i}guez, {Mar{\'i}a de la Luz}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.jiac.2018.04.001",
language = "American English",
pages = "928--931",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",

}

Case report: Identification of recombinant HCV genotype 1b–2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir. / Uribe-Noguez, Luis Antonio; Ocaña-Mondragón, Alicia; Mata-Marín, José Antonio; Cázares-Cortázar, Allison; Ribas-Aparicio, Rosa María; Gómez-Torres, María Elena; Gaytán-Martínez, Jesus; Martínez-Rodríguez, María de la Luz.

In: Journal of Infection and Chemotherapy, 01.11.2018, p. 928-931.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Case report: Identification of recombinant HCV genotype 1b–2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir

AU - Uribe-Noguez, Luis Antonio

AU - Ocaña-Mondragón, Alicia

AU - Mata-Marín, José Antonio

AU - Cázares-Cortázar, Allison

AU - Ribas-Aparicio, Rosa María

AU - Gómez-Torres, María Elena

AU - Gaytán-Martínez, Jesus

AU - Martínez-Rodríguez, María de la Luz

PY - 2018/11/1

Y1 - 2018/11/1

N2 - © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Hepatitis C virus (HCV) infection is a global health problem. HCV has been classified into seven genotypes and >67 subtypes. Genotyping is necessary to enable selection of appropriate treatments. The commercial molecular techniques currently used do not identify some HCV subtypes, mixed infections and recombinant forms. In this study, the core–E1 and NS5B regions were sequenced and phylogenetically analysed to identify infections by HCV recombinant genotype 1b–2b in two patients who had initially been diagnosed with HCV genotype 2 infection by reverse hybridization with a Versant HCV Genotype 2.0 Assay. Response to treatment was monitored by viral kinetics. Therapeutic failure occurred with initial treatment with PEGylated interferon-α2b and ribavirin, but the use of sofosbuvir and daclatasvir on a re-treatment regimen after reclassification of the infecting virus resulted in a sustained virologic response. The use of a sequencing approach in treatment-naïve infected patients could enable physicians to select the optimal therapy and avoid possible relapses and adverse reactions associated with antiviral therapy.

AB - © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Hepatitis C virus (HCV) infection is a global health problem. HCV has been classified into seven genotypes and >67 subtypes. Genotyping is necessary to enable selection of appropriate treatments. The commercial molecular techniques currently used do not identify some HCV subtypes, mixed infections and recombinant forms. In this study, the core–E1 and NS5B regions were sequenced and phylogenetically analysed to identify infections by HCV recombinant genotype 1b–2b in two patients who had initially been diagnosed with HCV genotype 2 infection by reverse hybridization with a Versant HCV Genotype 2.0 Assay. Response to treatment was monitored by viral kinetics. Therapeutic failure occurred with initial treatment with PEGylated interferon-α2b and ribavirin, but the use of sofosbuvir and daclatasvir on a re-treatment regimen after reclassification of the infecting virus resulted in a sustained virologic response. The use of a sequencing approach in treatment-naïve infected patients could enable physicians to select the optimal therapy and avoid possible relapses and adverse reactions associated with antiviral therapy.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047210492&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85047210492&origin=inward

U2 - 10.1016/j.jiac.2018.04.001

DO - 10.1016/j.jiac.2018.04.001

M3 - Article

C2 - 29773440

SP - 928

EP - 931

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

ER -